The effect of antiviral therapy for patients with HBeAg-negative cirrhosis

• Published in: Zhonghua shi yan he lin chuang bing du xue za ji Vol. 24; no. 1; p. 45
• Main Authors: Jie, Yu-Sheng, Chen, Lu-Biao, Shu, Xin, Yang, Xiao-An, Zhang, Ka, Xu, Qi-Huan, Li, Gang
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2010
• Subjects: Adult; Aged; Alanine Transaminase - blood; Antiviral Agents - therapeutic use; Case-Control Studies; China; Female; Hepatitis B e Antigens - blood; Humans; Liver Cirrhosis - blood; Liver Cirrhosis - drug therapy; Liver Cirrhosis - physiopathology; Liver Function Tests; Male; Middle Aged; Treatment Outcome; Young Adult; China
• ISSN: 1003-9279

To investigate the efficacy of nucleot(s)ide analogues therapy in patients with HBeAg-negative cirrhosis in China. 111 patiens with HBeAg-negative cirrhosis were divided into antiviral group (58 cases, 25 entecavir, 19 adefovir dipivoxil, 13 lamivudine, 1 telbivudine) and control group (53 cases, supportive and symptomatic treatment). These two groups were matched for demography, liver function and Child-Pugh score. At the 96th week, the rate of ALT normalization and HBV DNA drop (1g copies/ml) in antiviral group were higher than those in control group (P < 0.05). The rates of HBV DNA negative (< 500 copies/ml) were 88.7% (47/53) and 32. 5% (13/40), respectively (P < 0.05 ). There were no differences in the rates of developing HCC and undergoing variceal bleeding between antiviral group and control group (P > 0.5). 15.4% patients with lamivudine treatment emerged YMDD mutations. 10.5% patients with adefovir dipivoxil treatment emerged virologic breakthrough and hepatitis flare during the second year. 2 patien